On November 9, oncologists from more than 70 clinical research centers and experts from clinical trial institutions gathered in Guangzhou to participate in the multi-center, randomized controlled, open-label Phase III study of "Evaluating the efficacy and safety of YL201 for injection versus Topotecan hydrochloride for injection in patients with recurrent small cell lung cancer" organized by MediLink Therapeutics. Based on the availability of SCLC treatment in today's market and unmet clinical needs, in-depth exchanges and high-quality discussions were conducted regarding the design, preliminary clinical data, phase II study of YL201 and YL201-CN-302-01 research plan.
2024-11-09
Suzhou, China and Cambridge, Massachusetts, USA, October 18th, 2024 - MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces the appointment of Bruce Chabner, M.D., as Senior Strategic Advisor. Dr. Chabner will serve as a key Scientific Advisory Board member to the MediLink leadership team and bring his significant expertise in medical oncology to help strengthen MediLink’s global development efforts on its next-generation antibody drug conjugate pipelines.
2024-10-18
Suzhou, China, October 8, 2024 - MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply agreement with Amgen Inc. Amgen will lead a global clinical study to evaluate the therapeutic potential of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and Amgen's DLL3- and CD3-targeting bispecific T-cell engager (BiTE®) IMDELLTRA™ in extensive-stage small cell lung cancer (ES-SCLC) under the clinical trial collaboration and supply agreement. MediLink will provide the investigational drug YL201 for the combination study.
2024-10-08
2022-04-12Learn more
2021-03-01Learn more
